Association of pharmaceutical industry payments to physicians with prescription and medicare expenditures for pimavanserin

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: This study aimed to quantify the association between pharmaceutical industry payments to physicians for pimavanserin and both pimavanserin prescription volume and Medicare expenditures. Methods: This retrospective cross-sectional study used 2016 and 2017 data from Open Payments and the Medicare Part D Prescriber Public Use Files. The authors used Poisson regression models to quantify the association between physician payments for pimavanserin and pimavanserin prescription volume and linear regression models to quantify the association with Medicare expenditures for pimavanserin. Results: Of 1,609 physicians who prescribed pimavanserin, 45% received payments, which totaled to $6,369,922. Each $10,000 in physician payments was associated with a 14% increase in pimavanserin prescription volume (incident rate ratio=1.14, 95% confidence interval [CI]=1.13-1.14). Every $100 in physician payments was associated with a $175.84 increase in Medicare pimavanserin expenditures (95% CI=$161.55-$190.13). Conclusions: Extensive physician payments have been associated with increased pimavanserin prescription volume and Medicare expenditures.

Original languageEnglish (US)
Pages (from-to)77-80
Number of pages4
JournalPsychiatric Services
Volume72
Issue number1
DOIs
StatePublished - Jan 1 2021
Externally publishedYes

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Association of pharmaceutical industry payments to physicians with prescription and medicare expenditures for pimavanserin'. Together they form a unique fingerprint.

Cite this